WVE

GSK is expected to report a year-over-year earnings decline of 5.4% to $1.40 per share for Q3 2026, despite revenues rising 2.4% to $11.8 billion. With a negative Earnings ESP of -4.56% and Zacks Rank #4, the stock is not considered a compelling earnings-beat candidate. The company has historically beaten estimates in recent quarters, but recent analyst revisions suggest bearish sentiment on near-term earnings prospects.

Over 200 companies are advancing next-generation obesity therapies, with more than 30 drugs in late-stage development and 180+ in mid and early stages. Key players include Eli Lilly, Novo Nordisk, Viking Therapeutics, and Roche, developing innovative mechanisms like dual GLP-1/GIP receptor agonists and triple hormone receptor agonists. Recent approvals include Novo Nordisk's oral Wegovy formulation and Eli Lilly's orforglipron, while multiple Phase III trials show promising weight loss results.